Physician profile
Nicola Longo
NPI 1275612749
$294,952.19
in general payments reported to CMS, 2019-2025
22 companies · $49K in 2025
The $49K reported for 2025 was more than what 94% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $20K · 2021: $19K · 2022: $42K · 2023: $70K · 2024: $60K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Travel and Lodging: $72K · Food and Beverage: $3,278 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $100,678.68 |
| Travel and Lodging | $72,016.68 |
| Food and Beverage | $3,278.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,413.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $73,247.92 | 2021-2025 | |
| Biomarin Pharmaceutical INC. | $64,198.84 | 2019-2025 | Palynziq |
| Genzyme Corporation | $50,101.50 | 2022-2023 | |
| Chiesi USA, INC. | $23,567.75 | 2022-2025 | Lamzede, Elfabrio |
| Horizon Therapeutics Plc | $14,714.09 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $11,927.25 | 2019-2023 | |
| Modernatx, INC. | $10,859.28 | 2023-2024 | |
| Amicus Therapeutics, INC. | $10,500.00 | 2021-2024 | |
| Amgen INC. | $8,791.48 | 2024 | Ravicti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $6,206.90 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $4,501.08 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,500.00 | 2020 | |
| Recordati_rare_diseases_inc. | $4,459.00 | 2021-2022 | |
| Spark Therapeutics, INC. | $2,400.00 | 2021 | |
| Cycle Pharmaceuticals INC | $1,762.10 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Innovation | $1,715.00 | 2024 | Iqirvo |
| Leadiant Biosciences, INC. | $1,500.00 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicola Longo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.